1.6225  0.053 (3.34%)		09-16 11:09
Open: 1.595 High: 1.63 Volume: 585,346		Pre. Close: 1.57 Low: 1.5821 Market Cap: 1,211(M)

Short term
Mid term
Targets	6-month :	2.02	1-year :	2.36
Resists	First :	1.73	Second :	2.02
Pivot price	1.55
Supports	First :	1.47	Second :	1.32
MAs	MA(5) :	1.55	MA(20) :	1.53
	MA(100) :	1.36	MA(250) :	1.33
MACD	MACD :	0	Signal :	0
%K %D	K(14,3) :	43.2	D(3) :	38.7
RSI	RSI(14): 59.1
52-week	High :	1.73	Low :	0.98

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.
[ OPK ] has closed below upper band by 31.9%. Bollinger Bands are 15% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	1.57 - 1.58	1.58 - 1.59
Low:	1.52 - 1.54	1.54 - 1.55
Close:	1.55 - 1.57	1.57 - 1.59

OPKO Health, Inc. operates as a healthcare enterprise with a dual focus on diagnostics and pharmaceuticals. Its operations span the United States, Ireland, Chile, Spain, Israel, Mexico, and other international markets. The company's Diagnostics division encompasses BioReference Laboratories, which delivers a comprehensive suite of laboratory testing services. These services are crucial for disease detection, diagnosis, evaluation, monitoring, and treatment, covering areas such as esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare. BioReference serves a diverse client base, including medical practices, clinics, hospitals, employers, and government entities. Additionally, this segment provides a cutting-edge diagnostic instrument system designed for immediate, point-of-care blood test results, alongside its specialized 4Kscore testing for prostate cancer. Within the Pharmaceutical segment, OPKO offers a range of therapeutic products and a robust development pipeline. Key offerings include Rayaldee, indicated for the management of secondary hyperparathyroidism in adults suffering from stage 3 or 4 chronic kidney disease and vitamin D insufficiency. The pipeline features OPK88004, an investigational orally administered selective androgen receptor modulator; OPK88003, a peptide administered once weekly currently in Phase IIb trials for the treatment of type 2 diabetes and obesity; and hGH-CTP, a once-weekly human growth hormone injection that has successfully completed Phase III clinical trials in collaboration with Pfizer, Inc. A core strategy for this segment involves the development and commercialization of proprietary, extended-release versions of existing therapeutic proteins. Furthermore, OPKO Health supplies specialty active pharmaceutical ingredients (APIs) and is involved in the development, manufacturing, marketing, and sale of pharmaceutical, nutraceutical, veterinary, and ophthalmic products. The company also commercializes food supplements and over-the-counter products, produces and sells items primarily within the generics market, and handles the import, marketing, distribution, and sales of pharmaceutical products across various therapeutic areas, including cardiovascular conditions, vaccines, antibiotics, gastro-intestinal ailments, and hormone-related treatments, among others. Its pharmaceutical operations are further bolstered by platforms situated in Ireland, Chile, Spain, and Mexico. Founded in 1991, OPKO Health, Inc. maintains its corporate headquarters in Miami, Florida.

Sun, 13 Sep 2026
OPKO Health (OPK) Cashes In A Future Royalty Stream Early - finance.yahoo.com

Fri, 11 Sep 2026
OPKO Health Pivots to Therapeutics, Eyes Data-Rich 12 to 18 Months - finance.yahoo.com

Thu, 10 Sep 2026
OPKO Health (OPK) Stock Looks Rich As Cash Flow Risks Cloud Fair Value - simplywall.st

Tue, 08 Sep 2026
OPKO Health to Participate in the Wells Fargo 21st Annual Healthcare Conference - markets.businessinsider.com

Tue, 01 Sep 2026
BlackRock Inc. Takes Position in OPKO Health, Inc. $OPK - MarketBeat

Fri, 28 Aug 2026
Income Statement - OPKO Health, Inc.

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Outperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Underperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Medical - Diagnostics & Research
Shares Out	746 (M)
Shares Float	324 (M)
Held by Insiders	50.5 (%)
Held by Institutions	27.5 (%)
Shares Short	33,650 (K)
Shares Short P.Month	33,640 (K)

EPS	-0.08
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	1.59
Profit Margin	-12.4 %
Operating Margin	-15.4 %
Return on Assets (ttm)	-5.6 %
Return on Equity (ttm)	-5.9 %
Qtrly Rev. Growth	4.3 %
Gross Profit (p.s.)	0.15
Sales Per Share	0.78
EBITDA (p.s.)	-0.11
Qtrly Earnings Growth	0 %
Operating Cash Flow	-123 (M)
Levered Free Cash Flow	55 (M)

PE Ratio	-22.86
PEG Ratio	93.6
Price to Book value	1
Price to Sales	2.03
Price to Cash Flow	-9.68

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.